Dengue Literature Review

Secondary Dengue Infection

4 min read

Secondary Dengue Infection

Overview

Secondary dengue infection refers to infection with a DENV serotype different from a prior primary infection. It is the single most important risk factor for severe dengue (DHF/DSS). During secondary infection, pre-existing cross-reactive but non-neutralising antibodies from the primary infection can enhance viral uptake into Fc receptor-bearing cells (antibody-dependent enhancement, ADE), leading to higher viraemia, greater immune activation, and increased risk of vascular permeability and haemorrhagic complications.

Key Points from Literature

Epidemiological risk

  • Severe dengue (DHF/DSS) occurs predominantly in secondary heterotypic infections — this is the core observation underlying the ADE hypothesis (see Antibody-Dependent Enhancement)
  • Third and fourth infections are typically mild or asymptomatic, suggesting that broad immunity develops after exposure to 2+ serotypes (see Guzman2016 - Dengue Infection)
  • A longer interval between primary and secondary infection increases DHF risk: in Cuba, a 20-year interval (DENV-2, 1981→2001) produced ~8× higher DHF rates than a 4-year interval; waning neutralising antibody levels may shift the balance toward enhancement (see Guzman2016 - Dengue Infection)

Immunological features

  • Anamnestic IgG response: In secondary infection, IgG rises within 1–2 days of illness onset at high titres (≥1,280 by HI), unlike primary infection where IgG appears around day 7–10 (see IgM-IgG Serology ELISA)
  • IgG:IgM ratio > 1.2 is used in research settings to classify secondary infection
  • Complement activation proceeds via the classical pathway in secondary infection (immune complexes), vs. alternative pathway in primary (see Dengue Pathophysiology)
  • sNS1 blood levels correlate with disease severity specifically in secondary infection, not in primary (see Viraemia)

Serotype-specific patterns

Asymptomatic secondary infection

  • Not all secondary infections are symptomatic: in the 2006 Cuban DENV-4 epidemic, among individuals with prior DENV-1 exposure (secondary dengue), the overt:subclinical ratio was approximately 1:1 (see Garcia2010 - Asymptomatic Dengue FcγRIIa Polymorphism)
  • FcγRIIa-RR131 genotype was significantly associated with asymptomatic outcome in secondary infection, suggesting host genetics modulate whether ADE leads to clinical disease (see FcγRIIa Receptor)

Antibody kinetics: primary vs secondary divergence (Bos2025)

Bos2025 - Longitudinal Antibody Dynamics After Dengue (PREPRINT) provides the most detailed comparison of antibody trajectories across primary and secondary infection currently in this wiki, in a Nicaraguan pediatric cohort (n=79, DENV-1/DENV-3, followed to 18M):

PREPRINT — not peer reviewed.

  • Secondary infection kinetics are more compressed and attenuated at 18M relative to primary — consistent with rapid memory recall and faster contraction in a primed host, rather than the sustained expansion seen after primary exposure
  • Cross-reactive E-IgG (XR E-IgG) rises 6–18M post-primary (t½ = −2.13y), suggesting active accumulation of the cross-reactive pool in the inter-infection window — the pool most likely to mediate ADE upon secondary challenge (see Cross-Reactive Antibodies)
  • NS1-IgG wanes post-primary (t½ ≈ 2.1y), following the classical type-specific decay model; secondary kinetics show similar waning pattern
  • The divergence between primary (rising XR E-IgG, waning NS1-IgG) and secondary (attenuated 18M responses overall) suggests that the immunological state entering a potential tertiary infection is qualitatively different from the state entering secondary infection, in ways the classical ADE model does not fully capture

Diagnostic classification

  • Primary vs secondary infection classification relies on serology (IgG:IgM ratio, paired sera), PRNT, and HI assay (see IgM-IgG Serology ELISA, PRNT)
  • In the Sungnak2025 cohort, PRNT combined with HI assay was used for primary/secondary classification

Contradictions & Debates

  • The relationship between secondary infection and severe disease is probabilistic, not deterministic — host genetics, infecting serotype sequence, inter-infection interval, and viral genotype all modulate outcome
  • Whether ADE is the primary mechanism or whether T-cell original antigenic sin and cytokine-mediated pathology contribute independently remains debated (see Original Antigenic Sin, T Cell Responses in Dengue)
  • CYD-TDV (Dengvaxia) vaccination of seronegatives created an ADE-like state mimicking secondary infection upon natural exposure — raising the question of whether vaccine-induced and naturally-acquired enhancing antibodies behave identically (see CYD-TDV)

Sources

Graph View

Backlinks